ArticlePNAS nexus2022
Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients.
Article in PNAS nexus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Association between Guillain-Barré syndrome and SARS-CoV-2 virus infection, including the impact of COVID-19 vaccination in the context of the development and general clinical characteristics of the disease.Journal of neurovirology · 2025Pooled it
- Guillain-Barré syndrome and SARS-CoV-2 infection: a systematic review and meta-analysis on a debated issue and evidence for the 'Italian factor'.European journal of neurology · 2024Pooled it
- Xenosialylation as immunological chimerism: a host-centered unifying model for viral and post-vaccination immune complications.European cytokine network · 2026Review
- Immunomodulatory Mechanisms Underlying Neurological Manifestations in Long COVID: Implications for Immune-Mediated Neurodegeneration.International journal of molecular sciences · 2025Review
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19.Microbial cell factories · 2024Article
- Site-Specific O-glycosylation of SARS-CoV-2 Spike Protein and Its Impact on Immune and Autoimmune Responses.Cells · 2024Review
- Role of Xenosialylation in Post-Infectious and Post-Vaccination Complications, Including Covid-19 and Anti-SARS-CoV-2 Vaccination.Journal of inflammation research · 2024Article
- Review
- Advances in glycoscience to understand viral infection and colonization.Nature methods · 2022Article
- Article
- Reply to: The antibody response to the glycan α-Gal correlates with COVID-19 symptoms.Journal of medical virology · 2021Article
- Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19.Vaccines · 2021Article
- Glyconanomaterials for Human Virus Detection and Inhibition.Nanomaterials (Basel, Switzerland) · 2021Review
- Article
- Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barré syndrome.Brain : a journal of neurology · 2021Article
- Design, Synthetic Strategies, and Therapeutic Applications of Heterofunctional Glycodendrimers.Molecules (Basel, Switzerland) · 2021Article
- Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production.Frontiers in molecular biosciences · 2021Review
- Profile of Immunoglobulin GFrontiers in immunology · 2021Article
- IgA Nephropathy After SARS-CoV-2 Vaccination.Kidney medicineArticle
Corrections and comments
- Update of
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Our immune system is critical for preventing and treating SARS-CoV-2 infections, but aberrant immune responses can have deleterious effects. While antibodies to glycans could recognize the virus and influence the clinical outcome, little is known about their roles. Using a carbohydrate antigen microarray, we profiled serum antibodies in healthy control subjects and COVID-19 patients from two separate cohorts. COVID-19 patients had numerous autoantibodies to self-glycans, including antiganglioside antibodies that can cause neurological disorders. Additionally, nearly all antiglycan IgM signals were lower in COVID-19 patients, indicating a global dysregulation of this class of antibodies. Autoantibodies to certain
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.